Proposals to streamline regulatory approval of new drugs would bode well for biotech companies like Amgen in Thousand Oaks. New products and sales outside the U.S. drove up earnings for Amgen as the world’s biggest biotech company looks ahead to upcoming launches and continues to look for ways to deploy its cash. Increasingly, that cash…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
